Moderna's stock surged over 10% following the first U.S. avian influenza A (H5N1) death, as the company develops a vaccine.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback